Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer
Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new cancer treatments, has announced that the U.S. Food and…